RxDoctor Payments Data

Shishir Mathur, MD

Cardiovascular Disease · Glastonbury, CTNPI 1003016957

Payments from drug & device makers

$11,978in general payments, 2019–2025

Across 298 payments — averaging $40.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Philips North America LLC$2K
  • Boston Scientific$866
  • Amgen$728
  • Medtronic$709
  • Pfizer$550
  • plus $5K from 35 others

What the payments were for

  • Travel & lodging$3,02625%
  • Food & beverage$8,90574%
  • Education$470%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,978 in reported general payments places this provider in the 80th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$215,938
Medicare patients
1,238
Services billed
2,387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban152$217,945
XareltoRivaroxaban49$63,316
EntrestoSacubitril/Valsartan40$51,245
OzempicSemaglutide39$43,258
BrilintaTicagrelor25$25,915
JardianceEmpagliflozin15$21,339
Ranolazine ErRanolazine36$4,375
Metoprolol Succinate332$3,454
Atorvastatin Calcium240$1,932
Prasugrel Hcl15$1,697
Diltiazem 24hr Er (Cd)Diltiazem Hcl59$1,291
FenofibrateFenofibrate Nanocrystallized31$1,210
ClopidogrelClopidogrel Bisulfate121$1,129
Rosuvastatin Calcium126$1,109
Amiodarone Hcl22$1,053

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$550$217,945152 claims
Johnson & JohnsonXarelto$227$63,31649 claims
NovartisEntresto$495$51,24540 claims
Novo NordiskOzempic$264$43,25839 claims
AstraZenecaBrilinta$224$25,91525 claims
Boehringer IngelheimJardiance$191$21,33915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Glastonbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →